Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026
Regulatory
Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Press Releases
Interim Report April – December 2025
Regulatory
During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26
EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd].
Notice of extraordinary general meeting in EQL Pharma AB
Regulatory
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the extraordinary general meeting to be held on Tuesday 3 February 2026 at 13.00 at the company’s premises at Stortorg...
EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)
Regulatory
As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for th...